Department of Oral Medicine and Diagnostic Sciences, Faculty of Dentistry, Al-Farabi Colleges, Riyadh, Saudi Arabia.
São Leopoldo Mandic Medical & Dental Institute and Research Center, Campinas, SP, Brazil.
J Oral Pathol Med. 2018 Feb;47(2):97-103. doi: 10.1111/jop.12603. Epub 2017 Jul 5.
DNA aneuploidy is an imbalance of chromosomal DNA content that has been highlighted as a predictor of biological behavior and risk of malignant transformation. To date, DNA aneuploidy in oral potentially malignant diseases (OPMD) has been shown to correlate strongly with severe dysplasia and high-risk lesions that appeared non-dysplastic can be identified by ploidy analysis. Nevertheless, the prognostic value of DNA aneuploidy in predicting malignant transformation of OPMD remains to be validated. The aim of this meta-analysis was to assess the role of DNA aneuploidy in predicting malignant transformation in OPMD. The questions addressed were (i) Is DNA aneuploidy a useful marker to predict malignant transformation in OPMD? (ii) Is DNA diploidy a useful negative marker of malignant transformation in OPMD? These questions were addressed using the PECO method. Five studies assessing aneuploidy as a risk marker of malignant change were pooled into the meta-analysis. Aneuploidy was found to be associated with a 3.12-fold increased risk to progress into cancer (RR=3.12, 95% CI 1.86-5.24). Based on the five studies meta-analyzed, "no malignant progression" was more likely to occur in DNA diploid OPMD by 82% when compared to aneuploidy (RR=0.18, 95% CI 0.08-0.41). In conclusion, aneuploidy is a useful marker of malignant transformation in OPMD, although a diploid result should be interpreted with caution.
DNA 非整倍体是染色体 DNA 含量的不平衡，已被强调为生物行为和恶性转化风险的预测因子。迄今为止，口腔潜在恶性疾病（OPMD）中的 DNA 非整倍体与重度发育不良和高风险病变强烈相关，这些病变通过ploidy 分析可以识别为非发育不良。然而，DNA 非整倍体预测 OPMD 恶性转化的预后价值仍有待验证。本荟萃分析旨在评估 DNA 非整倍体在预测 OPMD 恶性转化中的作用。提出的问题是：(i) DNA 非整倍体是否是预测 OPMD 恶性转化的有用标志物？(ii) DNA 二倍体是否是 OPMD 恶性转化的有用阴性标志物？这些问题使用 PECO 方法进行了探讨。五项评估非整倍体作为恶性变化风险标志物的研究被纳入荟萃分析。结果发现，非整倍体与癌症进展的风险增加 3.12 倍相关（RR=3.12，95%CI 1.86-5.24）。基于荟萃分析的五项研究，与非整倍体相比，DNA 二倍体 OPMD 发生“无恶性进展”的可能性增加了 82%（RR=0.18，95%CI 0.08-0.41）。总之，DNA 非整倍体是 OPMD 恶性转化的有用标志物，但应谨慎解释二倍体结果。
